OBJECTIVES: Serum prostate specific antigen (PSA) screening has led to clinical and pathologic stage migration. We examined patients treated by radical prostatectomy between 1987 and 2005 to establish temporal trends in pathologic stage migration as assessed by the proportion of patients with nonorgan-confined disease (NOCD). METHODS: Step-sectioned prostatectomy specimens of 3364 consecutively treated patients were evaluated by year. The data were modeled by joinpoint regression, and the optimal model was selected by a Bayesian information criterion. RESULTS: From 1987 to 2005, the population underwent pathologic stage migration toward more organ-confined tumors (P <0.0001). The proportion of patients with NOCD exhibited changes in trend at 1992 and 1995. After widespread implementation of PSA screening, stage migration accelerated between 1992 and 1995. Since 1995, stage migration has substantially slowed but continues at an annual change of -4.2% (P = 0.0027). CONCLUSIONS: The presence of NOCD at prostatectomy has declined substantially in the PSA era. Recent slowing in this trend suggests a diminishing effect of PSA screening on pathologic stage migration.
OBJECTIVES: Serum prostate specific antigen (PSA) screening has led to clinical and pathologic stage migration. We examined patients treated by radical prostatectomy between 1987 and 2005 to establish temporal trends in pathologic stage migration as assessed by the proportion of patients with nonorgan-confined disease (NOCD). METHODS: Step-sectioned prostatectomy specimens of 3364 consecutively treated patients were evaluated by year. The data were modeled by joinpoint regression, and the optimal model was selected by a Bayesian information criterion. RESULTS: From 1987 to 2005, the population underwent pathologic stage migration toward more organ-confined tumors (P <0.0001). The proportion of patients with NOCD exhibited changes in trend at 1992 and 1995. After widespread implementation of PSA screening, stage migration accelerated between 1992 and 1995. Since 1995, stage migration has substantially slowed but continues at an annual change of -4.2% (P = 0.0027). CONCLUSIONS: The presence of NOCD at prostatectomy has declined substantially in the PSA era. Recent slowing in this trend suggests a diminishing effect of PSA screening on pathologic stage migration.
Authors: Deborah J del Junco; Erin E Fox; Sharon Cooper; Marc Goldhagen; Erik Koda; David Rogers; Edith Canby-Hagino; Jeri Kim; Curtis Pettaway; Douglas D Boyd Journal: J Urol Date: 2011-04-15 Impact factor: 7.450
Authors: Sarah Hawley; Ladan Fazli; Jesse K McKenney; Jeff Simko; Dean Troyer; Marlo Nicolas; Lisa F Newcomb; Janet E Cowan; Luis Crouch; Michelle Ferrari; Javier Hernandez; Antonio Hurtado-Coll; Kyle Kuchinsky; Janet Liew; Rosario Mendez-Meza; Elizabeth Smith; Imelda Tenggara; Xiaotun Zhang; Peter R Carroll; June M Chan; Martin Gleave; Raymond Lance; Daniel W Lin; Peter S Nelson; Ian M Thompson; Ziding Feng; Lawrence D True; James D Brooks Journal: Adv Anat Pathol Date: 2013-01 Impact factor: 3.875
Authors: S P Porten; A Smith; A Y Odisho; M S Litwin; C S Saigal; P R Carroll; M R Cooperberg Journal: Prostate Cancer Prostatic Dis Date: 2014-05-13 Impact factor: 5.554
Authors: Karynsa Cetin; Jennifer L Beebe-Dimmer; Jon P Fryzek; Richard Markus; Michael A Carducci Journal: Urology Date: 2009-12-06 Impact factor: 2.649
Authors: Eric A Klein; Fernando J Bianco; Angel M Serio; James A Eastham; Michael W Kattan; J Edson Pontes; Andrew J Vickers; Peter T Scardino Journal: J Urol Date: 2008-04-18 Impact factor: 7.450